Archives
Can Targeted Rabbit Pharming Raise Protein Yield?
2026-11-09
A 2025 study reports unusually high milk concentrations of a reporter protein from rabbits carrying a targeted insertion at the endogenous CSN2 locus. The result supports a promising expression strategy, but its generalizability to therapeutic proteins and industrial production remains uncertain.
Targeted Expression in Rabbit Pharming
2026-11-09
A 2025 study linked a recombinant reporter gene to the rabbit CSN2 milk-protein locus and reported substantially higher milk concentrations than historical conventional-transgenic examples. The result supports locus-aware expression as a promising research strategy, but the evidence remains specific to one reporter, one rabbit line, and a concentration-based readout.
Calcium-Lactate Nanomedicine in Colorectal Cancer
2026-11-08
The cited study presents a calcium-lactate nanoparticle that combines bufalin delivery with CD47-targeting CRISPR/Cas9 to link tumor-cell stress, macrophage reprogramming, and antitumor immunity. This editorial separates the study’s preclinical nanomedicine findings from the analytical role of an associated high-fidelity PCR reagent and examines the evidence limits around pyroptosis, gene editing, metastasis control, and translation.
What the High-Yield Rabbit Pharming Study Shows
2026-11-07
A 2025 study reported unusually high milk concentrations of a fluorescent reporter after targeted insertion at the rabbit CSN2 locus. The result supports a compelling biological hypothesis about endogenous mammary-gland regulation, but its small animal-level dataset and reporter-based design limit how confidently it can be generalized to therapeutic proteins or industrial production.
What High-Yield Rabbit Pharming Data Really Show
2026-11-06
A 2025 study links targeted insertion at the rabbit CSN2 locus with markedly higher reporter-protein levels in milk, but the evidence remains a proof of biological feasibility rather than validation of a therapeutic manufacturing platform.
When Context Changes p53 mRNA Results
2026-11-06
A p53 mRNA result can reflect cargo expression, nanoparticle trafficking, immune activation, combination treatment, or tumor biology. This editorial separates those causal layers and explains why findings from different models, formulations, comparators, and readouts should not be treated as interchangeable evidence.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-05
A targeted rabbit line produced substantially more recombinant reporter protein in milk than historical conventional-transgenic benchmarks, but the comparison is not yet a definitive test of therapeutic manufacturing performance. The key uncertainties concern construct-specific biology, limited animal replication, product quality, and whether the yield advantage generalizes across proteins.
CSN2-Directed Expression in Rabbit Pharming
2026-11-05
A 2025 study tested whether targeted placement of a reporter gene at the rabbit CSN2 milk-protein locus could improve recombinant protein output. The reported 15–20 g/L range is notable, but its generalizability remains limited by the reporter construct, the small number of high-producing animals, and the absence of a matched conventional-transgenic control.
How CSN2 Knock-In Raised Rabbit Pharming Yield
2026-11-04
A 2025 study tested whether placing a reporter transgene at the rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenic lines. The resulting homozygous animals produced reported tdTomato concentrations of 15–20 g/L in milk, but the evidence remains an early proof of principle because it rests on a small number of animals and a fluorescent reporter rather than a therapeutic protein.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-04
A targeted rabbit line produced markedly higher reporter-protein concentrations in milk than historical conventional lines, but the evidence remains a small proof-of-concept rather than a controlled demonstration of general therapeutic-production performance.
Diminazene Aceturate in ACE2 Cardiomyopathy Research
2026-11-03
A preclinical study used Diminazene Aceturate as a pharmacological probe of ACE2 signaling in sepsis-induced cardiomyopathy. The findings support a protective association involving the ACE2–MasR–Sirt1 axis and mitochondrial biogenesis, while leaving target specificity, causal ordering and clinical relevance unresolved.
Why the CSN2 Locus Raised Rabbit Pharming Yield
2026-11-03
A targeted integration strategy placed a reporter gene under the control of the rabbit CSN2 milk-protein promoter. The resulting line reached 15–20 g/L tdTomato in milk from two homozygous females, while the study’s design and limited animal-level evidence leave important questions about reproducibility, product quality, and transferability to therapeutic proteins.
From CSN2 Targeting to Rabbit Pharming Yield
2026-11-02
A literature-focused analysis of how targeted insertion at the rabbit CSN2 locus was linked to high tdTomato concentrations in milk, and what the study does—and does not—establish about animal pharming.
When Context Changes a Biological Yield
2026-11-02
A high milk concentration can demonstrate strong expression in a particular genetic and physiological context without establishing therapeutic performance, manufacturing consistency, or broad applicability.
A CSN2-Targeted Strategy for Rabbit Pharming
2026-11-01
A literature-focused analysis of a 2025 study that used targeted insertion at the rabbit CSN2 milk-protein locus to increase recombinant reporter production, with emphasis on mechanism, comparative evidence, and limits to translation.